Cancer inhibition mechanism of lung cancer mouse model based on dye trace method

Wei Zhang1, Hongyan Shu2, Lixin Fang1

  • 1Department of Thoracic Surgery, Linzi District People's Hospital, Zibo City 255400, China.

Insights

A combination of shikonin, aconitine, and notoginsenoside R1 significantly reduced lung cancer incidence in mice. This compound therapy offers a promising strategy for cancer prevention and treatment.

Area of Science:

  • Pharmacology
  • Oncology
  • Biochemistry

Background:

  • Cancer remains a leading cause of mortality worldwide.
  • Understanding drug inhibition mechanisms is crucial for developing effective cancer therapies.
  • Natural compounds offer potential for novel anti-cancer treatments.

Purpose of the Study:

  • To investigate the anti-cancer mechanism of shikonin, aconitine, and notoginsenoside R1.
  • To evaluate the efficacy of a compound formulation in preventing lung cancer.
  • To explore the impact of these compounds on lung barrier permeability and cellular markers.

Main Methods:

  • Dye trace method to assess lung barrier permeability.
  • Histopathological analysis using Hematoxylin and Eosin (H.E.) staining.
  • Immunohistochemical staining and Western blot for protein expression analysis.

Main Results:

  • The model group exhibited 100% lung cancer incidence with increased lung barrier permeability and altered protein expression.
  • Intervention with individual drugs showed moderate improvements.
  • The compound group demonstrated a significant reduction in lung cancer incidence to 8.3%.

Conclusions:

  • The combination of shikonin, aconitine, and notoginsenoside R1 exhibits a potent anti-cancer effect against lung cancer.
  • This compound therapy improves histopathological changes and reduces cancer incidence.
  • The findings provide a theoretical basis for further clinical research in cancer treatment.

Related Concept Videos